var data={"title":"Topical cocaine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Topical cocaine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5937?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=topical-cocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Topical cocaine: Pediatric drug information&quot;</a> and <a href=\"topic.htm?path=topical-cocaine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Topical cocaine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154123\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Local Anesthetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154110\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Anesthesia:</b> Topical: Dosage depends on the area to be anesthetized, tissue vascularity, technique of anesthesia, and individual patient tolerance; the lowest dose necessary to produce adequate anesthesia should be used; concentrations of 1% to 10% may be used, with 4% being the most frequently used concentration (maximum total dose: 3 mg/kg <b>or</b> 200 mg) (Liao 1999; McGee 2010). Lasts for 30 minutes or longer depending on concentration and vascularity of anesthetized tissue. Use reduced dosages for children, elderly, or debilitated patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28625102\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=topical-cocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Topical cocaine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Children and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154111\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28625103\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28625104\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154089\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, External, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4% (4 mL, 10 mL); 10% (4 mL [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154073\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154125\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154092\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Topical: Use only on mucous membranes of the oral, laryngeal, and nasal cavities. Do not use on extensive areas of broken skin. May apply with cotton applicators, as a spray, or instill directly into mucous cavity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154091\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Topical anesthesia (and vasoconstriction) for mucous membranes of the oral, laryngeal, or nasal cavities.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154080\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Use of the topical solution may produce systemic reactions from excessive and rapid absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Epistaxis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Decreased heart rate (low doses), myocardial infarction (Lenders 2013; Makaryus 2006), tachycardia, vasoconstriction, ventricular arrhythmia (Lenders 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Central nervous system depression (may follow CNS excitation), central nervous system stimulation, excitation, nervousness, restlessness, tonic-clonic seizures</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Tremor</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Corneal changes (epithelium sloughing), corneal ulcer, mydriasis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Increased blood pressure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154095\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cocaine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154077\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease or risk factors for cardiovascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cocaine abuse: Use with caution in patients with a history of cocaine abuse. In patients being treated for cardiovascular complication of cocaine abuse, avoid beta-blockers for treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acutely ill patients: Use with caution in acutely ill; reduce dose consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated patients: Use with caution in debilitated patients; reduce dose consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; reduce dose consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use with caution in children; reduce dose consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: Consider anesthesia safe in a cocaine-abusing patient when obvious signs of intoxication are not exhibited (eg, tachycardia, hypertension, hyperthermia, ECG changes including QRS and QT<sub>c</sub> interval prolongation &gt;500 msec) (Hill 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For topical use only. Limit to office and surgical procedures only. Not for ophthalmic use; causes sloughing of the corneal epithelium. Use caution in patients with severely traumatized mucosa and sepsis in the region of the proposed application.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Trained personnel: Clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154119\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154082\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10133&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: Cocaine (Topical) may enhance the tachycardic effect of Cannabinoid-Containing Products. <b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Cocaine (Topical) may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: Cocaine (Topical) may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: Cocaine (Topical) may enhance the hypertensive effect of Sympathomimetics.  Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154084\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13862039\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with this product. Cocaine rapidly crosses the placenta in concentrations equal to those in the mother. Adverse events occur in the fetus (eg, congenital malformations, growth restriction), infant (neonatal abstinence syndrome), and mother (eg, preterm labor, placental abruption) following maternal abuse (Fajemirokun-Odudeyi, 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154098\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Cocaine rapidly enters breast milk. Irritability, hypertension, tachypnea, tachycardia, and tremors have been reported in nursing infants (Chasnoff, 1987).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154086\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Vital signs</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154076\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ester local anesthetic blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction; interferes with the uptake of norepinephrine by adrenergic nerve terminals producing vasoconstriction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154094\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Following topical administration to mucosa:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: ~1 minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: ~5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration (dose dependent): &ge;30 minutes; cocaine metabolites may appear in urine of neonates up to 5 days after birth due to maternal cocaine use shortly before birth</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Well absorbed through mucous membranes (~35% absorbed when applied intranasally with cottonoid pledget) (Liao 1999); enhanced by inflammation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: &sim;2 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic; major metabolites are ecgonine methyl ester and benzoyl ecgonine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 75 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily urine (&lt;10% as unchanged drug and metabolites); cocaine metabolites may appear in the urine of neonates for up to 5 days after birth due to maternal cocaine use shortly before birth</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323076\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cocaine HCl External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4% (4 mL): $223.12</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038586\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Kokain (DK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Beckman KJ, Parker RB, Hariman RJ, et al, &ldquo;Hemodynamic and Electrophysiological Actions of Cocaine. Effects of Sodium Bicarbonate as an Antidote in Dogs,&rdquo; <i>Circulation</i>, 1991, 83(5):1799-807.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topical-cocaine-drug-information/abstract-text/1850669/pubmed\" target=\"_blank\" id=\"1850669\">1850669</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brogan WC 3d, Lange RA, Glamann DB, et al, &ldquo;Recurrent Coronary Vasoconstriction Caused by Intranasal Cocaine; Possible Role for Metabolites,&rdquo; <i>Ann Intern Med</i>, 1992, 116(7):556-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topical-cocaine-drug-information/abstract-text/1543310/pubmed\" target=\"_blank\" id=\"1543310\">1543310</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chasnoff IJ, Lewis DE, and Squires L, &ldquo;Cocaine Intoxication in Breast-Fed Infants,&rdquo; <i>Pediatrics</i>, 1987, 80(6):836-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topical-cocaine-drug-information/abstract-text/3684393/pubmed\" target=\"_blank\" id=\"3684393\">3684393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cocaine hydrochloride [prescribing information]. Philadelphia, PA: Cody Laboratories; March 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fajemirokun-Odudeyi O and Lindow SW, &quot;Obstetric Implications of Cocaine Use in Pregnancy: A Literature Review,&quot; <i>Eur J Obstet Gynecol Reprod Biol</i>, 2004, 112(1):2-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topical-cocaine-drug-information/abstract-text/14687731/pubmed\" target=\"_blank\" id=\"14687731\">14687731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fritsma GA, Leikin JB, Maturen AJ, et al, &ldquo;Detection of Anticardiolipin Antibody in Patients With Cocaine Abuse,&rdquo; <i>J Emerg Med</i>, 1991, 9(Suppl 1):37-43.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenglass EJ, &ldquo;The Adverse Effects of Cocaine on the Developing Human,&rdquo; Yaffe SJ and Arana JV, eds, <i>Pediatric Pharmacology: Therapeutic Principles in Practice</i>, 2nd ed, Philadelphia, PA: WB Saunders Co, 1992, 598-604.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hill GE, Ogunnaike BO, and Johnson ER, &ldquo;General Anaesthesia for the Cocaine Abusing Patient. Is it Safe?&rdquo;  <i>Br J Anaesth</i>, 2006, 97(5):654-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topical-cocaine-drug-information/abstract-text/16914461/pubmed\" target=\"_blank\" id=\"16914461\">16914461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hollander J, Hoffman RS, Shih RD, et al, &ldquo;Coronary Artery Disease in Patients With Cocaine Associated Myocardial Infarction,&rdquo; <i>Acad Emerg Med</i>, 1995, 2:456.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hollander JE, Burstein JL, Hoffman RS, et al, &ldquo;Cocaine-Associated Myocardial Infarction,&rdquo; <i>Chest</i>, 1995, 107(5):1237-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topical-cocaine-drug-information/abstract-text/7750312/pubmed\" target=\"_blank\" id=\"7750312\">7750312</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kain ZN, Kain TS, and Scarpelli EM, &ldquo;Cocaine Exposure in Utero: Perinatal Development and Neonatal Manifestations - Review,&rdquo; <i>Clin Toxicol</i>, 1992, 30:607-36.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kloner RA and Rezkalla SH, &ldquo;Cocaine and the Heart,&rdquo; <i>N Engl J Med</i>, 2003, 348(6):487-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topical-cocaine-drug-information/abstract-text/12571254/pubmed\" target=\"_blank\" id=\"12571254\">12571254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lange RA and Hillis LD, &ldquo;Cardiovascular Complications of Cocaine Use [published correction appears in <i>N Engl J Med</i>. 2001;345(19):1432]. <i>N Engl J Med</i>. 2001;345(5):351-358.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lenders GD, Jorens PG, De Meyer T, Vandendriessche T, Verbrugghe W, Vrints CJ. Coronary spasm after the topical use of cocaine in nasal surgery. <i>Am J Case Rep</i>. 2013;14:76-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topical-cocaine-drug-information/abstract-text/23569569/pubmed\" target=\"_blank\" id=\"23569569\">23569569</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liao BS, Hilsinger RL Jr, Rasgon BM, et al, &quot;A Preliminary Study of Cocaine Absorption From the Nasal Mucosa,&quot; <i>Laryngoscope</i>, 1999, 109(1):98-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topical-cocaine-drug-information/abstract-text/9917048/pubmed\" target=\"_blank\" id=\"9917048\">9917048</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Makaryus JN, Makaryus AN, Johnson M. Acute myocardial infarction following the use of intranasal anesthetic cocaine. <i>South Med J</i>.2006, 99(7):759-761.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topical-cocaine-drug-information/abstract-text/16866061/pubmed\" target=\"_blank\" id=\"16866061\">16866061</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McGhee DL. Local and Topical Anesthesia. Roberts JR and Hedges JR, eds. Clinical Procedures in Emergency Medicine. Philadephia, PA: WB Saunders Co, 2010, 481-498.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicholson KE and Rogers JE, &ldquo;Cocaine and Adrenaline Paste: A Fatal Combination?&rdquo; <i>Br Med J</i>, 1995, 311(6999):250-1.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richards CF, Clark RF, Holbrook T, et al, &ldquo;The Effect of Cocaine and Amphetamines on Vital Signs in Trauma Patients,&rdquo; <i>J Emerg Med</i>, 1995, 13(1):59-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topical-cocaine-drug-information/abstract-text/7782627/pubmed\" target=\"_blank\" id=\"7782627\">7782627</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shannon RP, Manders WT, and Shen YT, &ldquo;Role of Blood Doping in the Coronary Vasoconstrictor Response to Cocaine,&rdquo; <i>Circulation</i>, 1995, 92(1):96-105.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topical-cocaine-drug-information/abstract-text/7788924/pubmed\" target=\"_blank\" id=\"7788924\">7788924</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Todd K, Hollander JE, Heilpern K, et al, &ldquo;Prevalence of the Use of Cocaine in Patients With Chest Pain,&rdquo; <i>Acad Emerg Med</i>, 1995, 2:344.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trabulsy ME, &ldquo;Cocaine Washed Out Syndrome in a Patient With Acute Myocardial Infarction,&rdquo; <i>Am J Emerg Med</i>, 1995, 13(5):538-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topical-cocaine-drug-information/abstract-text/7662059/pubmed\" target=\"_blank\" id=\"7662059\">7662059</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10133 Version 126.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F154123\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F154110\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F28625102\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F154111\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F28625103\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F28625104\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F154089\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F154073\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F154125\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F154092\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F154091\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F154080\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F154095\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F154077\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F154119\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F154082\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F154084\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13862039\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F154098\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F154086\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F154076\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F154094\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323076\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038586\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10133|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=topical-cocaine-patient-drug-information\" class=\"drug drug_patient\">Topical cocaine: Patient drug information</a></li><li><a href=\"topic.htm?path=topical-cocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">Topical cocaine: Pediatric drug information</a></li></ul></div></div>","javascript":null}